The ESH-iCMLf 26th Annual John Goldman Conference on CML: Biology and Therapy, held in Prague, brought together world-leading experts to discuss the latest advancements in the treatment and biology of CML. Jointly organised bythe European School of Haematology (ESH) and the iCMLf , the event featured cutting-edge research presentations, insightful discussions, and collaborative sessions focused on driving innovation in CML management.
Thanks to everyone who supported the 2024 John Goldman Fun Run, held during the recent ESH-iCMLf 26th Annual John Goldman Conference on CML: Biology and Therapy in Prague.
Despite the cold morning, the warmth of camaraderie and the fun we shared among the around 50 enthusiastic runners joining us on the 5-km route through Potviní Park made it an unforgettable experience!
Together, we raised $2,200– a heartfelt thank you to all 64 individual supporters.
The funds raised will directly support our mission to improve outcomes for people living with CML in low- and middle-income countries, ensuring that physicians in these regions can continue to access the vital training and education needed to make a difference in patient care.
Read more...
The recently concluded ESH-iCMLf 26th Annual John Goldman Conference on CML: Biology and Therapy featured an exciting, cutting-edge, scientific program. This is a friendly reminder to attend the webinar with highlights of this meeting next Tuesday, October 8th at 13.00 CEST.
This live webinar is part of our ongoing iCMLf Conversations series
Your dial-in link for Zoom: https://us02web.zoom.us/j/85295994086
Expect highlights on new and often unpublished data, and the most innovative developments in CML – presented to you by Professors Jorge Cortes and Daniela Krause, both co-chairs of the conference. Some of the key sessions included new therapeutic approaches, TKI responses and biomarkers, progenitor cells and immunology, and the latest in blast phase CML treatments.
We're bringing you highlights from the conference with a summary of selected scientific sessions. Check back over the next couple of days for updates on more sessions.
This Scientific Session presented six top-scoring abstracts selected by the meeting organisers. These presentations highlighted key advancements in understanding the mechanisms of disease progression, the clinical implications of mutations, and factors driving relapse after CML cessation.
During this session, the best biological abstract was awarded to Daniele Sarnello for his work on BNIP3 as a potential therapeutic target in hypoxic CML cells, while the best clinical abstract went to Kendra Sweet, who presented results of the SWOG trial on the addition of ruxolitinib to BCR::ABL1 TKIs.
Continuing our series of CML education events around the world, the iCMLf recently hosted three Regional Discussion Group meetings for Latin America. These webinars bring together physicians and scientists to discuss specific challenges of managing CML across Latin America. The sessions covered; the choice and order of TKIs managing chronic treatment effects, strategies for stopping CML therapy, and applying the ELN laboratory guidelines in low- and middle-income countries. The sessions were attended by over 130 attendees from 15 countries.
We are incredibly grateful for the time and input from all of the experts and for support from Novartis for these meetings, which allowed simultaneous translation in Spanish and Portuguese.
The discussions highlighted five key themes:
We’d like to invite you to a new series of iCMLf facilitated discussions to support the learning needs of CML physicians in Pakistan, in partnership with the Pakistan Society of Haematology.